These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31094854)

  • 21. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
    Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
    Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab in inflammatory bowel disease. Is premedication necessary?
    Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
    Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
    van Schaik T; Maljaars JP; Roopram RK; Verwey MH; Ipenburg N; Hardwick JC; Veenendaal RA; van der Meulen-de Jong AE
    Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
    Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
    Drobne D; Kurent T; Golob S; Švegl P; Rajar P; Hanžel J; Koželj M; Novak G; Smrekar N; Ferkolj I; Štabuc B
    Aliment Pharmacol Ther; 2019 Apr; 49(7):880-889. PubMed ID: 30784100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis.
    Hayes MJ; Stein AC; Sakuraba A
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1177-85. PubMed ID: 24955449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
    Williet N; Paul S; Peyrin-Biroulet L; Roblin X
    Dig Dis Sci; 2016 Apr; 61(4):990-5. PubMed ID: 26669880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
    Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
    Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.
    Gold SL; Cohen-Mekelburg S; Schneider Y; Shen N; Faggen A; Rupert A; Scherl EJ; Bosworth B; Steinlauf A
    Inflamm Bowel Dis; 2017 Oct; 23(10):1882-1889. PubMed ID: 28837521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
    Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease.
    Minar P; Saeed SA; Afreen M; Kim MO; Denson LA
    J Pediatr Gastroenterol Nutr; 2016 May; 62(5):715-22. PubMed ID: 26551317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
    Iborra M; Herreras J; Boscá-Watts MM; Cortés X; Trejo G; Cerrillo E; Hervás D; Mínguez M; Beltrán B; Nos P
    Dig Dis Sci; 2019 Jun; 64(6):1612-1621. PubMed ID: 30604371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
    Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
    Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
    Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
    Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.